| Symbol | RXRX |
|---|---|
| Name | RECURSION PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 41 S RIO GRANDE STREET, SALT LAKE CITY, Utah, 84101, United States |
| Telephone | +1 385 269 - 0203 |
| Fax | — |
| — | |
| Website | https://www.recursion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001601830 |
| Description | Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Additional info from NASDAQ: |
📋 Gibson Christopher (Ex-Director) plans to sell 100K shares of RECURSION PHARMACEUTICALS, INC. (at $3.31 each, total $331K) Filed: Aug 13, 2026 | ID: 005979
Read more📋 Gibson Christopher (Ex-Director) plans to sell 50K shares of RECURSION PHARMACEUTICALS, INC. (at $3.37 each, total $168K) Filed: Aug 12, 2026 | ID: 005928
Read more📋 Gibson Christopher (Ex-Director) plans to sell 100K shares of RECURSION PHARMACEUTICALS, INC. (at $3.27 each, total $327K) Filed: Aug 10, 2026 | ID: 005848
Read more📋 Gibson Christopher (Ex-Director) plans to sell 100K shares of RECURSION PHARMACEUTICALS, INC. (at $3.25 each, total $325K) Filed: Aug 07, 2026 | ID: 005744
Read moreNew Form SCHEDULE 13G - RECURSION PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000530 <b>Size:</b> 8 KB
Read moreRecursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Read moreRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Read moreNew Form SCHEDULE 13G - RECURSION PHARMACEUTICALS, INC. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100121-26-000994 <b>Size:</b> 7 KB
Read more📋 Gibson Christopher (Ex-Director) plans to sell 75K shares of RECURSION PHARMACEUTICALS, INC. (at $3.00 each, total $225K) Filed: Jul 30, 2026 | ID: 005467
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid… | Phase1 | Solid Tumor | Recruiting | 2026-04-13 | 2029-03-01 | ClinicalTrials.gov |
| NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory … | Phase1 | Relapsed or Refractory B-cell Malignancies | Recruiting | 2025-03-31 | 2028-12-01 | ClinicalTrials.gov |
| NCT06678659 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Met… | Phase1 | Unresectable | Recruiting | 2024-11-21 | 2028-10-30 | ClinicalTrials.gov |
| NCT06536465 | The Clostridioides Difficile Trial of REC-3964 | Phase2 | Recurrent Clostridioides Difficile Infection | Terminated | 2024-10-14 | 2025-05-06 | ClinicalTrials.gov |
| NCT06005974 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mut… | Phase2 | AXIN1 Gene Mutation | Terminated | 2024-01-15 | 2025-02-24 | ClinicalTrials.gov |
| NCT05552755 | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Phase1 | Familial Adenomatous Polyposis | Recruiting | 2023-07-10 | 2027-09-01 | ClinicalTrials.gov |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | Phase1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | 2023-07-06 | 2028-05-01 | ClinicalTrials.gov |
| NCT05130866 | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis … | Phase2 | Neurofibromatosis Type 2 | Terminated | 2022-06-20 | 2025-08-18 | ClinicalTrials.gov |
| NCT05085561 | The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 | Phase2 | Cerebral Cavernous Malformation | Completed | 2022-03-17 | 2025-06-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Neurofibromatosis Type 2 | TERMINATED | NCT05130866 |
| REC-2282 | Other | Phase PHASE2 | Neurofibromatosis Type 2 | TERMINATED | NCT05130866 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| EXS73565 | Other | Phase PHASE1 | Relapsed or Refractory B-cell Malignancies | RECRUITING | NCT06980116 |
| Placebo | Other | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT05085561 |
| REC-994 | Other | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT05085561 |
| EXS73565 | Other | Phase PHASE1 | Relapsed or Refractory B-cell Malignancies | RECRUITING | NCT06980116 |
| EXS74539 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT07517198 |
| Placebo | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-4881 | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-1245 | Other | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| REC-1245 | Other | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| REC-1245 | Other | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| REC-1245 | Other | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| REC-1245 | Other | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| Placebo | Other | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT05085561 |
| REC-994 | Other | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT05085561 |
| REC-1245 | Other | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| Placebo | Other | Phase PHASE2 | Neurofibromatosis Type 2 | TERMINATED | NCT05130866 |
| REC-2282 | Other | Phase PHASE2 | Neurofibromatosis Type 2 | TERMINATED | NCT05130866 |
| REC-3964 | Other | Phase PHASE2 | Recurrent Clostridioides Difficile Infection | TERMINATED | NCT06536465 |
| EXS73565 | Other | Phase PHASE1 | Relapsed or Refractory B-cell Malignancies | RECRUITING | NCT06980116 |
| REC-4881 | Other | Phase PHASE2 | AXIN1 Gene Mutation | TERMINATED | NCT06005974 |
| EXS74539 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT07517198 |
| Placebo | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-4881 | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| SoC | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| Placebo | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-4881 | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| Placebo | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-4881 | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| Placebo | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-4881 | Other | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| EXS73565 | DRUG | Phase PHASE1 | Relapsed or Refractory B-cell Malignancies | RECRUITING | NCT06980116 |
| SoC | DRUG | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| GTAEXS617 | DRUG | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT05985655 |
| EXS74539 | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT07517198 |
| REC-1245 | DRUG | Phase PHASE1 | Unresectable | RECRUITING | NCT06678659 |
| REC-3964 | DRUG | Phase PHASE2 | Recurrent Clostridioides Difficile Infection | TERMINATED | NCT06536465 |
| REC-4881 | DRUG | Phase PHASE2 | AXIN1 Gene Mutation | TERMINATED | NCT06005974 |
| REC-2282 | DRUG | Phase PHASE2 | Neurofibromatosis Type 2 | TERMINATED | NCT05130866 |
| Placebo | DRUG | Phase PHASE1 | Familial Adenomatous Polyposis | RECRUITING | NCT05552755 |
| REC-994 | DRUG | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT05085561 |